7 March 2025
Notice of Annual General
Meeting
AstraZeneca PLC (the Company)
announced today the publication of its Notice of Annual General
Meeting 2025 and Shareholders' Circular (the Notice).
The Company's Annual General Meeting
(AGM) will be digitally-enabled and will be held on Friday 11 April
2025 at 14:30 (BST). Full details and joining instructions are set
out in the Notice.
The Notice and proxy form for the
AGM have been submitted to the National Storage Mechanism and will
shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Notice is also available on the Company's website at
www.astrazeneca.com/noticeofmeeting2025.
The Notice is being despatched to
shareholders today.
The business to be conducted at the
AGM is summarised below:
1. To receive the Company's
Accounts, the Reports of the Directors and Auditor and the
Strategic Report for the year ended 31 December 2024
2. To confirm the 2024
interim dividends
3. To re-appoint
PricewaterhouseCoopers LLP as Auditor
4. To authorise the
Directors to agree the remuneration of the Auditor
5. To elect or re-elect
Directors
6. To approve the annual
statement of the Chair of the Remuneration Committee and the Annual
Report on Remuneration for the year ended 31 December
2024
7. To authorise limited political donations
8. To authorise the
Directors to allot shares
9. To authorise the
Directors to disapply pre-emption rights
10. To authorise the Directors to
further disapply pre-emption rights for acquisitions and specified
capital investments
11. To authorise the Company to
purchase its own shares
12. To
reduce the notice period for general meetings
Pursuant to Regulation 41 of the
Uncertificated Securities Regulations 2001, only holders of
ordinary shares entered in the register of members of the Company
by 18:30 (BST) on 9 April 2025 (or their duly appointed proxies),
or if this meeting is adjourned, in the register of members by
18:30 (BST) two days prior to any adjourned meeting, are entitled
to attend or vote at the AGM in respect of the number of ordinary
shares registered in their name at that time. Changes to the
entries in the register of members after 18:30 (BST) on 9 April
2025, or if this meeting is adjourned, in the register of members
after 18:30 (BST) two days prior to any adjourned meeting, shall be
disregarded in determining the rights of any person to attend or
vote at the AGM. The Record Date applied to
the Euroclear Sweden system to determine entitlement to participate
and vote at the AGM is close of business on 2 April 2025.
The Record Date to determine entitlement to
participate and vote at the AGM for registered holders of the
Company's American Depositary Receipts is close of business on 25
February 2025.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is
a global, science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
